N30 Pharmaceuticals appoints R. Michael Carruthers new CFO

N30 Pharmaceuticals appoints R. Michael Carruthers new CFO

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on developing product candidates for cystic fibrosis, announced R. Michael Carruthers has been appointed... Read More

By: InnovatioNews Friday February 6, 2015 0 comments Tags: Array BioPharma, Boulder, Jon Congleton, N30 Pharmaceuticals, N91115

CBSA: 2014 was successful year for major bioscience financings, acquistions and expansions

CBSA: 2014 was successful year for major bioscience financings, acquistions and expansions

DENVER - The Colorado BioScience Association (CBSA) reports the state attained a number of key financings, acquisitions and expansions in its bioscience industry in 2014. "We've seen a... Read More

By: InnovatioNews Tuesday December 23, 2014 0 comments Tags: April Giles, CBSA, Clovis Oncology, Covidien, Denver, InDevR, N30 Pharmaceuticals, SomaLogic, Spectranetics, Terumo BCT

N30 Pharmaceuticals appoints Jon Congleton to be president and CEO

N30 Pharmaceuticals appoints Jon Congleton to be president and CEO

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage, biopharmaceutical company focused on development of therapies for cystic fibrosis, announced its board of directors has appointed Jon... Read More

By: InnovatioNews Tuesday December 23, 2014 0 comments Tags: Boulder, cystic fibrosis, Howard Furst, Jon Congleton, N30 Pharmaceuticals

N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced it raised $30 million in a mezzanine... Read More

By: InnovatioNews Monday November 24, 2014 0 comments Tags: Boulder, cystic fibrosis, Deerfield Management, Howard Furst, Jennison Associates, N30 Pharmaceuticals, N91115, Sabby Management

N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. announced it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis. The study is a multi-center,... Read More

By: Steve Friday March 15, 2013 0 comments Tags: Boulder, Charles Scoggin, cystic fibrosis, N30 Pharmaceuticals, N6022